Swartz, M, Blazer, D, George, L, Winfield, I.
Estimating the prevalence of borderline personality disorder in the community. J Personal Disord
1990; 4: 257–72.
Torgersen, S, Kringlen, E, Cramer, V.
The prevalence of personality disorders in a community sample. Arch Gen Psychiatry
2001; 58: 590–6.
Skodol, AE, Gunderson, JG, McGlashan, TH, Dyck, IR, Stout, RL, Bender, DS, Grilo, CM, Shea, MT, Zanarini, MC, Morey, LC, Sanislow, CA, Oldham, JM. Functional impairment in patients with schizotypal, borderline, avoidant, or obsessive–compulsive personality disorder. Am J Psychiatry
2002; 159: 276–83.
Stone, MH. Long-term outcome in personality disorders. Br J Psychiatry
1993; 162: 299–313.
Benedetti, F, Sforzini, L, Colombo, C, Maffei, C, Smeraldi, E.
Low-dose clozapine in acute and continuation treatment of severe borderline personality disorder. J Clin Psychiatry
1998; 59: 103–7.
Bogenschutz, MP, George, NH. Olanzapine versus placebo in the treatment of borderline personality disorder. J Clin Psychiatry
2004; 65: 104–9.
Frankenburg, FR, Zanarini, MC. Clozapine treatment of borderline patients: a preliminary study. Compr Psychiatry
1993; 34: 402–5.
Nickel, MK, Muehlbacher, M, Nickel, C, Kettler, C, Pedrosa, GF, Bachler, E, Buschmann, W, Rother, N, Fartacck, R, Egger, C, Anvar, J, Rother, WK, Loew, TH, Kaplan, P.
Aripiprazole in the treatment of patients with borderline personality disorder: a double-blind, placebo-controlled study. Am J Psychiatry
2006; 163: 833–8.
Rocca, P, Marchiaro, L, Cocuzza, E, Bogetto, F.
Treatment of borderline personality disorder with risperidone. J Clin Psychiatry
2002; 63: 241–4.
Soler, J, Pascual, JC, Campins, J, Barrachina, J, Puigdemont, D, Alvarez, E, Perez, V. Double-blind, placebo-controlled study of dialectical behavior therapy plus olanzapine for borderline personality disorder. Am J Psychiatry
2005; 162: 1221–4.
Zanarini, MC, Frankenburg, FR. Olanzapine treatment of female borderline personality disorder patients: a double-blind, placebo-controlled pilot study. J Clin Psychiatry
2001; 62: 849–54.
Zanarini, MC, Frankenburg, FR, Parachini, EA. A preliminary, randomized trial of fluoxetine, olanzapine, and the olanzapine-fluoxetine combination in women with borderline personality disorder. J Clin Psychiatry
2004; 65: 903–7.
Zanarini, MC, Schulz, SC, Detke, HC, Tanaka, Y, Zhao, F, Lin, D, DeBerdt, W, Corya, S.
A dose comparison of olanzapine for the treatment of borderline personality disorder: a 12-week randomized, double-blind, placebo-controlled study. Int J Neuropsychopharmacol
2006; 9 (suppl 1): s191.
Frankenburg, FR, Zanarini, MC. Divalproex sodium treatment of women with borderline personality disorder and bipolar II disorder: a double-blind placebo-controlled pilot study. J Clin Psychiatry
2002; 63: 442–6.
Soloff, PH, Lynch, KG, Kelly, TM, Malone, KM, Mann, JJ. Characteristics of suicide attempts of patients with major depressive episode and borderline personality disorder: a comparative study. Am J Psychiatry
2000; 157: 601–8.
Zanarini, MC, Vujanovic, AA, Parachini, EA, Boulanger, JL, Frankenburg, FR, Hennen, J.
Zanarini Rating Scale for Borderline Personality Disorder (ZAN–BPD): a continuous measure of DSM–IV borderline psychopathology. J Personal Disord
2003; 17: 233–42.
American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders (4th edn) . APA, 1994.
First, MB, Gibbon, M, Spitzer, RL, Williams, JBW. Structured Clinical Interview for DSM–IV–TR Axis I Disorders, Research Version, Patient Edition (SCID–I/P). Biometrics Research, New York State Psychiatric Institute, 2001.
Derogatis, LR, Savitz, KL. The SCL–90–R, brief symptom inventory and matching clinical rating scales. In The Use of Psychological Testing for Treatment Planning and Outcome Assessment (ed. Maruish, ME): 41–80. Lawrence Erlbaum Associates, 1999.
American Psychiatric Association. Global Assessment of Functioning (GAF) Scale. In Diagnostic and Statistical Manual of Mental Disorders (4th edn, text revision) (DSM–IV–TR): 32–4. APA, 2000.
Sheehan, DV, Harnett-Sheehan, K, Raj, BA. The measurement of disability. Int Clin Psychopharmacol
1996; 11 (suppl 3): 89–95.
Coccaro, EF, Harvey, PD, Kupsaw-Lawrence, E, Herbert, JL, Bernstein, DP. Development of neuropharmacologically based behavioral assessments of impulsive aggressive behavior. J Neuropsychiatry Clin Neurosci
1991; 3: s44–S51.
Montgomery, SA, Åsberg, M.
A new depression scale designed to be sensitive to change. Br J Psychiatry
1979; 134: 382–9.
Davidson, J, Turnbull, CD, Strickland, R, Miller, R, Graves, K.
The Montgomery–Åsberg depression rating scale: reliability and validity. Acta Psychiatr Scand
1986; 73: 544–8.
National Cholesterol Education Program. Third report of the National Cholesterol Education Program (NCEP) Expert Panel on detection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel III) final report. Circulation
2002; 106: 3143–421.
American Diabetic Assocation. Standards of medical care in diabetes. Diabetes Care
2004; 27 (suppl 1): s15–35.
Simpson, EB, Yen, S, Costello, E, Rosen, K, Begin, A, Pistorello, J, Pearlstein, T. Combined dialectical behavior therapy and fluoxetine in the treatment of borderline personality disorder. J Clin Psychiatry
2004; 65: 379–85.
Barnes, TR. A rating scale for drug-induced akathisia. Br J Psychiatry
1989; 154: 672–6.
Guy, W. ECDEU Assessment Manual for Psychopharmacology, Revised. US Department of Health, Education and Welfare, 1976.
Schulz, SC, Camlin, KL, Berry, SA, Jesberger, JA. Olanzapine safety and efficacy in patients with borderline personality disorder and comorbid dysthymia. Biol Psychiatry
1999; 46: 1429–35.
Khan, A, Kolts, RL, Rapaport, MH, Krishnan, KR, Brodhead, AE, Browns, WA. Magnitude of placebo response and drug-placebo differences across psychiatric disorders. Psychol Med
2005; 5: 743–9.
Walsh, BT, Seidman, SN, Sysko, R, Gould, M.
Placebo response in studies of major depression: variable, substantial, and growing. JAMA
2002; 287: 1840–7.
Goldberg, SC, Schulz, SC, Schulz, PM, Resnick, RJ, Hamer, RM, Friedel, RO. Borderline and schizotypal personality disorders treated with low-dose thiothixene vs placebo. Arch Gen Psychiatry
1986; 43: 680–6.
Tohen, M, Sanger, TM, McElroy, SL, Tollefson, GD, Chengappa, KN, Daniel, DG, Petty, F, Centorrino, F, Wang, R, Grundy, SL, Greaney, MG, Jacobs, TG, David, SR, Toma, V.
Olanzapine versus placebo in the treatment of acute mania. Am J Psychiatry
1999; 156: 702–9.
Tohen, M, Jacobs, TG, Grundy, SL, Banov, MC, McElroy, SL, Janicak, PG, Sanger, T, Risser, R, Zhang, F, Toma, V, Francis, J, Tollefson, GD, Breier, A.
Efficacy of olanzapine in acute bipolar mania: a double-blind, placebo-controlled study. Arch Gen Psychiatry
2000; 57: 841–9.
Soloff, PH, George, A, Nathan, RS, Schulz, PM, Ulrich, RF, Perel, JM. Progress in pharmacotherapy of borderline disorders. A double-blind study of amitriptyline, haloperidol, and placebo. Arch Gen Psychiatry
1986; 43: 691–7.
Cowdry, RW, Gardner, DL. Pharmacotherapy of borderline personality disorder. Alprazolam, carbamazepine, trifluoperazine, and tranylcypromine. Arch Gen Psychiatry
1988; 45: 111–9.
Cornelius, JR, Soloff, PH, Perel, JM, Ulrich, RF. A preliminary trial of fluoxetine in refractory borderline patients. J Clin Psychopharmacol
1991; 11: 116–20.
Markovitz, PJ, Calabrese, JR, Schulz, SC, Meltzer, HY. Fluoxetine in the treatment of borderline and schizotypal personality disorders. Am J Psychiatry
1991; 148: 1064–7.
Coccaro, EF, Kavoussi, RJ. Fluoxetine and impulsive aggressive behavior in personality–disordered subjects. Arch Gen Psychiatry
1997; 54: 1081–8.
Salzman, C, Wolfson, AN, Schatzberg, A, Looper, J, Henke, R, Albanese, M, Schwartz, J, Miyawaki, E. Effect of fluoxetine on anger in symptomatic volunteers with borderline personality disorder. J Clin Psychopharmacol
1995; 15: 23–9.
Markovitz, PJ, Wagner, SC. Venlafaxine in the treatment of borderline personality disorder. Psychopharmacol Bull
1995; 31: 773–7.
Hollander, E, Tracy, KA, Swann, AC, Coccaro, EF, McElroy, SL, Wozniak, P, Sommerville, KW, Nemeroff, CB. Divalproex in the treatment of impulsive aggression: efficacy in cluster B personality disorders. Neuropsychopharmacol
2003; 28: 1186–97.